Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer

Effective Pharmacotherapy
doi 10.33978/2307-3586-2019-15-24-38-46
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medforum

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy